NCT04256434View on ClinicalTrials.gov

A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2020

Primary Completion Date

May 29, 2020

Study Completion Date

May 29, 2020

Conditions
Health
Interventions
DRUG

Dinalbuphine sebacate

150 mg Dinalbuphine sebacate

DRUG

Nalbuphine HCl

20 mg Nalbuphine

Trial Locations (1)

90630

WCCT Global Inc., Cypress

Sponsors
All Listed Sponsors
lead

Lumosa Therapeutics Co., Ltd.

INDUSTRY